Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibition

2002, Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143

Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646

Rao, 1982, The Cincinnati lipid research clinic family study: cultural and biological determinants of lipids and lipoprotein concentrations, Am J Hum Genet, 34, 888

Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat Genet, 34, 154, 10.1038/ng1161

Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol, J Biol Chem, 279, 48865, 10.1074/jbc.M409699200

Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat Struct Mol Biol, 14, 413, 10.1038/nsmb1235

Park, 2004, Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver, J Biol Chem, 279, 50630, 10.1074/jbc.M410077200

Horton, 2003, Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes, Proc Natl Acad Sci U S A, 100, 12027, 10.1073/pnas.1534923100

Maxwell, 2003, Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice, J Lipid Res, 44, 2109, 10.1194/jlr.M300203-JLR200

Jeong, 2008, Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2, J Lipid Res, 49, 399, 10.1194/jlr.M700443-JLR200

Dubuc, 2004, Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia, Arterioscler Thromb Vasc Biol, 24, 1454, 10.1161/01.ATV.0000134621.14315.43

Browning, 2010, Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans, J Lipid Res, 51, 3359, 10.1194/jlr.P009860

Persson, 2010, Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans, Arterioscler Thromb Vasc Biol, 30, 2666, 10.1161/ATVBAHA.110.214130

Persson, 2009, Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors, Endocrinology, 150, 1140, 10.1210/en.2008-1281

Langhi, 2008, Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes, FEBS Lett, 582, 949, 10.1016/j.febslet.2008.02.038

Cameron, 2008, Berberine decreases PCSK9 expression in HepG2 cells, Atherosclerosis, 201, 266, 10.1016/j.atherosclerosis.2008.02.004

Feingold, 2008, Inflammation stimulates the expression of PCSK9, Biochem Biophys Res Commun, 374, 341, 10.1016/j.bbrc.2008.07.023

Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc Natl Acad Sci U S A, 100, 928, 10.1073/pnas.0335507100

Essalmani, 2011, In vivo evidence that furin from hepatocytes inactivates PCSK9, J Biol Chem, 286, 4257, 10.1074/jbc.M110.192104

Qian, 2007, Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis, J Lipid Res, 48, 1488, 10.1194/jlr.M700071-JLR200

Nassoury, 2007, The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR, Traffic, 8, 718, 10.1111/j.1600-0854.2007.00562.x

Zhang, 2007, Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, J Biol Chem, 282, 18602, 10.1074/jbc.M702027200

Yamamoto, 2011, A two step binding model of PCSK9 interaction with the low density lipoprotein receptor, J Biol Chem, 286, 5464, 10.1074/jbc.M110.199042

Maxwell, 2005, Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment, Proc Natl Acad Sci U S A, 102, 2069, 10.1073/pnas.0409736102

Poirier, 2008, The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2, J Biol Chem, 283, 2363, 10.1074/jbc.M708098200

Liu, 2010, PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain, J Lipid Res, 51, 2611, 10.1194/jlr.M006635

Luo, 2009, Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice, J Lipid Res, 50, 1581, 10.1194/jlr.M800542-JLR200

Mayer, 2008, Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels, J Biol Chem, 283, 31791, 10.1074/jbc.M805971200

Blesa, 2008, A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia, J Clin Endocrinol Metab, 93, 3577, 10.1210/jc.2008-0269

Shioji, 2004, Genetic variants in PCSK9 affect the cholesterol level in Japanese, J Hum Genet, 49, 109, 10.1007/s10038-003-0114-3

Miyake, 2008, Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population, Atherosclerosis, 196, 29, 10.1016/j.atherosclerosis.2006.12.035

Fasano, 2007, A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol, Arterioscler Thromb Vasc Biol, 27, 677, 10.1161/01.ATV.0000255311.26383.2f

Zhao, 2006, Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote, Am J Hum Genet, 79, 514, 10.1086/507488

Berge, 2006, Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy, Arterioscler Thromb Vasc Biol, 26, 1094, 10.1161/01.ATV.0000204337.81286.1c

Fasano, 2009, Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells, Atherosclerosis, 203, 166, 10.1016/j.atherosclerosis.2008.10.027

Homer, 2008, Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa, Atherosclerosis, 196, 659, 10.1016/j.atherosclerosis.2007.07.022

Cohen, 2005, Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9, Nat Genet, 37, 161, 10.1038/ng1509

Cameron, 2008, Characterization of novel mutations in the catalytic domain of the PCSK9 gene, J Intern Med, 263, 420, 10.1111/j.1365-2796.2007.01915.x

Allard, 2005, Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia, Hum Mutat, 26, 497, 10.1002/humu.9383

Kotowski, 2006, A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol, Am J Hum Genet, 78, 410, 10.1086/500615

Bourbon, 2008, Familial hypercholesterolaemia in Portugal, Atherosclerosis, 196, 633, 10.1016/j.atherosclerosis.2007.07.019

Dubuc, 2010, A new method for measurement of total plasma PCSK9: clinical applications, J Lipid Res, 51, 140, 10.1194/jlr.M900273-JLR200

Cameron, 2009, Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage, Atherosclerosis, 203, 161, 10.1016/j.atherosclerosis.2008.10.007

Pisciotta, 2006, Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia, Atherosclerosis, 186, 433, 10.1016/j.atherosclerosis.2005.08.015

Timms, 2004, A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree, Hum Genet, 114, 349, 10.1007/s00439-003-1071-9

Leren, 2004, Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia, Clin Genet, 65, 419, 10.1111/j.0009-9163.2004.0238.x

Naoumova, 2005, Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response, Arterioscler Thromb Vasc Biol, 25, 2654, 10.1161/01.ATV.0000190668.94752.ab

Norata, 2010, Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles, Atherosclerosis, 208, 177, 10.1016/j.atherosclerosis.2009.06.023

Hooper, 2007, The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population, Atherosclerosis, 193, 445, 10.1016/j.atherosclerosis.2006.08.039

Cameron, 2006, Effect of mutations in the PCSK9 gene on the cell surface LDL receptors, Hum Mol Genet, 15, 1551, 10.1093/hmg/ddl077

Cariou, 2009, PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia, Arterioscler Thromb Vasc Biol, 29, 2191, 10.1161/ATVBAHA.109.194191

Lagace, 2006, Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice, J Clin Invest, 116, 2995, 10.1172/JCI29383

Lakoski, 2009, Genetic and metabolic determinants of plasma PCSK9 levels, J Clin Endocrinol Metab, 94, 2537, 10.1210/jc.2009-0141

Baass, 2009, Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents, Clin Chem, 55, 1637, 10.1373/clinchem.2009.126987

Cui, 2010, Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population, Atherosclerosis, 213, 632, 10.1016/j.atherosclerosis.2010.09.027

Alborn, 2007, Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol, Clin Chem, 53, 1814, 10.1373/clinchem.2007.091280

Welder, 2010, High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol, J Lipid Res, 51, 2714, 10.1194/jlr.M008144

Ouguerram, 2004, Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9, Arterioscler Thromb Vasc Biol, 24, 1448, 10.1161/01.ATV.0000133684.77013.88

Lambert, 2006, Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor, Endocrinology, 147, 4985, 10.1210/en.2006-0098

Lalanne, 2005, Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells, J Lipid Res, 46, 1312, 10.1194/jlr.M400396-JLR200

Chan, 2009, Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?, Clin Chem, 55, 2049, 10.1373/clinchem.2009.128645

Careskey, 2008, Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9, J Lipid Res, 49, 394, 10.1194/jlr.M700437-JLR200

Troutt, 2010, Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels, J Lipid Res, 51, 345, 10.1194/jlr.M000620

Lambert, 2008, Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment, Clin Chem, 54, 1038, 10.1373/clinchem.2007.099747

Nilsson, 2007, Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression, Biochem Biophys Res Commun, 357, 707, 10.1016/j.bbrc.2007.03.196

Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc Natl Acad Sci U S A, 102, 5374, 10.1073/pnas.0501652102

Cohen, 2006, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N Engl J Med, 354, 1264, 10.1056/NEJMoa054013

Chan, 2009, A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates, Proc Natl Acad Sci U S A, 106, 9820, 10.1073/pnas.0903849106

Graham, 2007, Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice, J Lipid Res, 48, 763, 10.1194/jlr.C600025-JLR200

Frank-Kamenetsky, 2008, Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates, Proc Natl Acad Sci U S A, 105, 11915, 10.1073/pnas.0805434105

Gupta, 2010, A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo, PLoS One, 5, e10682, 10.1371/journal.pone.0010682

Ni, 2011, A proprotein convertase subtilisin-like/kexin type 9 (PCSK9)-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces free circulating PCSK9 and LDL-cholesterol, J Lipid Res, 52, 78, 10.1194/jlr.M011445

Ni, 2011, A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo, J Lipid Res, 52, 78, 10.1194/jlr.M011445

Seidah, 2007, The proprotein convertases are potential targets in the treatment of dyslipidemia, J Mol Med, 85, 685, 10.1007/s00109-007-0172-7

Grefhorst, 2008, Plasma PCSK9 preferentially reduces liver LDL receptors in mice, J Lipid Res, 49, 1303, 10.1194/jlr.M800027-JLR200

Hedrick, 2009, Targeting PCSK9 for the treatment of hypercholesterolemia, Curr Opin Investig Drugs, 10, 938